Future Landscape in High-risk Prostate Cancer and Metastatic Prostate Cancer
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by Medknow in UroCancer Clinics of India
- Vol. 2 (1) , 37-44
Abstract
Summary: The management of high-risk and advanced prostate cancer had a major paradigm shift over the past decade. From the Huggins’ era of sole androgen deprivation therapy (ADT), the management has evolved to novel androgen receptor signaling inhibitors (ARSI), chemotherapy, targeted molecular, immunotherapy, and radiotheranostics. The management of advanced prostate cancer is broadly studied under metastatic hormone or castration-sensitive prostate cancer (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC). The mCSPC has evolved from mere ADT to the use of abiraterone, enzalutamide, and docetaxel-based chemotherapy and the burning conflict of treatment intensification with triplet therapy. Various novel agents, such as poly (ADP-ribose) polymerase inhibitors (PARPIs) and radiotheranostics, are being explored in the management of mCSPC. The management of mCRPC has evolved from mitoxantrone to docetaxel-based therapy, novel ARSI therapy, PARPI, 177 lutetium-prostate-specific membrane antigen-617, or novel-targeted therapy.Keywords
This publication has 61 references indexed in Scilit:
- CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trialInvestigational New Drugs, 2024
- First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate CancerJAMA Oncology, 2023
- 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)Annals of Oncology, 2021
- Advanced Prostate Cancer: Treatment Advances and Future DirectionsTrends in Cancer, 2020
- Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate CancerCell Reports, 2019
- Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate CancerEuropean Urology, 2019
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint BlockadeJAMA Oncology, 2019
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate CancerJournal of Urology, 2014
- Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004